Are Korean Biopharma Alliances Recovering After Gloomy Year?
Trend Toward Higher Upfronts
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
You may also be interested in...
Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players.
Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.